Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Venetoclax for elderly AML patients

Mark Levis • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Venetoclax

The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination regimens. Speaking at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses how this, along with allogenic transplantation, has changed the way in which elderly AML patients are now being treated.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mark Levis

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
0:46
Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
Mark Levis • 12 Jun 2026
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
0:53
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
Mark Levis • 12 Jun 2026
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
1:39
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
Mark Levis • 5 Dec 2025
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
2:03
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis • 5 Dec 2025

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals